Showing 891-900 of 5092 results for "".
COVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execValeant's Plan for Derm; VCS Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-valeant-s-plan-for-derm-vcs-highlights/18587/Amid reports that its Obagi and Solta units may be sold off, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Vegas Cosmetic Surgery has wrapped up its 12th program, gathering dermatologists, plastic surgeons, facial pFDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Clinical Data on a New Therapeutic for AD
https://practicaldermatology.com/series/dermwire-tv/clinical-data-on-a-new-therapeutic-for-ad/37270/Rafael Amado, MD, head of global research and development for Zai Lab, discusses new preclinical data presented at the European Academy of Allergy and Clinical Immunology Congress 2025 on an IL-13IL-31R bispecific antibody for the treatment of atopic dermatitis.DermWireTV: Skyrizi for PsA; Toxins and Wound Healing at Maui Derm; SDDS Registration
https://practicaldermatology.com/topics/psoriasis/skyrizi-for-psa-toxins-and-wound-healing-at-maui-derm-sdds-registration-dermwiretv/20057/Skyrizi (AbbVie) is now approved for the treatment of adults with active psoriatic arthritis. Michael Gold, MD was among the speakers who offered updates on cosmetic trends as well as medical care at Maui Dermatology for Dermatologists last week. He spoke about high-dose neurotoxins. Robert KirsnerAdvances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.Inclusivity: A Concerted Effort
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/inclusivity-a-concerted-effort/19915/Historical events and recent developments contribute to some patients’ skepticism of medicine in general and dermatology specifically. Hear what panelists say about the best approaches to expand inclusivity in research, clinical trials, and patient care. It will take a concerted effort to overcome cCOVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do not